WHO ICTRP trial
Multicenter prospective single-arm study of PD-1 antibody SHR-1210 for…
ChiCTR2000033396 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2000033396 |
|---|---|
| Public title | Multicenter prospective single-arm study of PD-1 antibody SHR-1210 for neoadjuvant and adjuvant maintenance therapy in resectable primary liver cancer |
| Scientific title | Multicenter prospective single-arm study of PD-1 antibody SHR-1210 for neoadjuvant and adjuvant maintenance therapy in resectable primary liver cancer |
| Primary sponsor | Sun Yat-sen Memorial Hospital, Sun Yat-sen University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 4 |
| Countries | China |
| Conditions | Hepatocellular carcinoma |
| Interventions | Case series:SHR-1210 intravenous medication |
| Registration date | May 31, 2020 |
| Target size | Case series:92 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: